Traditional snakebite antivenom relies on a century-old technology. To find safer and more effective treatments for one of the world’s most neglected tropical diseases, scientists are designing new therapies, ranging from camel nanobodies to human recombinant antibodies and small molecule drugs.
As the science on vaccination and natural infection-based immunity against COVID-19 variants continues to evolve, accurately communicating study results and their limitations has never been more important.
Researchers no longer think that proteins blindly swim through the cytoplasm hoping to bump into one another. Instead, they intentionally aggregate with other biomolecules, forming membrane free, transient organelles called condensates.
Clinicians, researchers, and communicators are developing more effective strategies to disseminate information about clinical trials to reach a wider audience. They ultimately expect that this will lead to more inclusive trials.
There are now more cancer treatment options than ever before. However, almost all of them face the same major challenge: eventually, they stop working. There are several unique ways in which cancer cells evade death. Now, scientists are inventing new technologies to target these mechanisms and overcome resistance.
COVID-19 has gotten a little better at infecting cells and dodging antibodies with each set of mutations in new variants. Omicron is the best at dodging antibodies, but its modified structure sacrificed virulence for antibody resistance.